Quick Facts

• Utilized for the prevention and management of deep vein thrombosis (DVT).
• Employed to reduce the risk of blood clot formation in high-risk patients.
• Used in the context of certain acute cardiac conditions.

Fraxodi is a medication indicated for therapeutic and prophylactic use in various vascular conditions. Its main purpose is to support the management of thromboembolic disorders.

The medication is employed to prevent the development of blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in individuals undergoing general or orthopedic surgery who are at increased risk of these events. Additionally, it is used for patients with severely limited mobility due to acute illness, such as respiratory or cardiac failure.

In a therapeutic context, Fraxodi is utilized as part of a treatment plan for existing deep vein thrombosis and pulmonary embolism. It also offers a supportive role in the management of certain acute coronary syndromes, including unstable angina and non-Q wave myocardial infarction.

Official Eligibility Profile for Fraxodi

The eligibility for using Fraxodi (Nadroparin Calcium) is strictly defined by regulatory documents, primarily focusing on patient conditions that increase the risk of bleeding or impede drug clearance. The medicine is primarily approved for use in adults (ge 18 years) for its labeled indications.

Absolute Contraindications (Must Not Use)

Fraxodi is contraindicated in several specific populations due to the high risk of serious complications, as stated in the regulatory label:

• Patients with Hypersensitivity to nadroparin or other Low Molecular Weight Heparins (LMWHs).
• Individuals with active major bleeding or a history of cerebral hemorrhage.
• Patients with current or previous Heparin-Induced Thrombocytopenia (HIT).
• Patients with severe renal impairment (Creatinine Clearance < 30 mL/min), except during hemodialysis.
• Patients with severe, unmanageable high blood pressure or acute infective endocarditis.

Restricted and Non-Recommended Use

• Pediatric Population: Use in children and adolescents (< 18 years) is not recommended due to insufficient data on safety and efficacy in this age group.
• Organ Function: Patients with moderate renal impairment (CrCl 30 to 50 mL/min) or who are older adults require caution and close monitoring of kidney function.
• Pregnancy and Lactation: Use during pregnancy requires a careful assessment of benefits and risks. Use while breastfeeding is not recommended.

Fraxodi’s official regulatory interaction profile is defined primarily by its classification as an antithrombotic agent, leading to documented additive pharmacodynamic effects with other substances that affect blood clotting. The profile includes constraints related to specific procedural co-administration and established physiological limitations on drug clearance.

Documented Pharmacodynamic Interactions

Co-administration with the following classes of products is documented to increase the overall risk of haemorrhage or bleeding complications due to additive effects on haemostasis:

Interaction Type	Interacting Product Categories
Increased Bleeding Risk	Oral Anticoagulants, Platelet Inhibitors, NSAIDs, Thrombolytic Agents, Systemic Glucocorticosteroids
Increased Hyperkalemia Risk	Medicinal products that increase serum potassium (e.g., certain ACE inhibitors)

Official Restrictions and Exposure Constraints

Regulatory documentation establishes strict limitations on co-administration for certain procedures and patient conditions:

• Contraindicated Combination: The curative dose of Fraxodi is explicitly contraindicated for co-administration with Spinal or Epidural Anaesthesia or Lumbar Puncture due to the associated risk of spinal hematoma.
• Dose Constraint: The use of prophylactic doses in combination with these neuraxial procedures requires extreme caution and individual assessment, as documented in official prescribing information.
• Population Exposure Modifier: Severe renal impairment (creatinine clearance below 30 ml/min) is classified as a condition that reduces the drug’s clearance, resulting in increased plasma exposure and heightened risk, leading to contraindication.

Fraxodi, which contains nadroparin calcium, is a low molecular weight heparin (LMWH) that exerts its pharmacodynamic effect by selectively binding to antithrombin III (ATIII). The binding of nadroparin to ATIII induces a conformational change in ATIII, significantly accelerating its natural inhibitory activity. This allosteric potentiation targets several activated coagulation factors, primarily and most potently activated Factor X (Factor Xa).

The Factor Xa-ATIII-nadroparin ternary complex formation inactivates Factor Xa, a serine protease essential to the intrinsic and extrinsic pathways of the coagulation cascade. Inhibition of Factor Xa blocks the downstream conversion of prothrombin (Factor II) to thrombin (Factor IIa). The resulting reduction in thrombin availability subsequently limits the proteolytic cleavage of fibrinogen to fibrin monomers, a critical step in the formation of the insoluble fibrin polymer network. This disruption of the terminal coagulation pathway leads to system-level physiological modulation that manifests as diminished velocity and magnitude of fibrin clot formation within the vasculature.

Fraxodi (nadroparin calcium) is an injectable medicine provided in a pre-filled syringe. Its administration must strictly follow the official instructions for use.

Official Administration Guidelines

Guideline Component	Instructions as Labeled
Route of Administration	Subcutaneous injection (under the skin). Never administer by the intramuscular route.
Dosing Rules	The prescribed dose is calculated by a healthcare professional based on the patient's body weight and the specific condition being treated
Frequency and Timing	Generally administered once daily or twice daily (every 12 hours), depending on the treatment regimen.
Preparation	For pre-filled syringes, the small air bubble should not be expelled before the injection to prevent loss of solution.
Age-Specific Use	Use in children and adolescents (under 18) is not recommended due to insufficient data to determine dosing. Dose adjustment is generally not necessary for the elderly unless kidney function is impaired.
Missed Dose	If a dose is missed, it should be administered as soon as the patient remembers, unless the next dose is due within a short time. In that case, the missed dose should be skipped, and the patient should return to the regular dosing schedule. A double dose must never be injected to compensate for a missed one.

Procedural Steps for Injection

Fraxodi must be administered into a pinched-up fold of skin on the lateral abdominal wall (at least 5 cm below the navel); the thigh is an alternative site. The needle should be inserted vertically or at a 45-degree angle. After the injection is complete, the site must not be rubbed.

Fraxodi: Recent Clinical Evidence

This section summarizes the primary findings from clinical research into nadroparin calcium (Fraxodi), focusing on what the studies evaluated and the patterns reported in the evidence.

---

Evidence for Preventing Blood Clots (VTE Prophylaxis)

Research exploring VTE prevention is largely based on randomized controlled trials (RCTs) conducted on adults. In the setting of major orthopedic and general surgery, studies monitored the rate of deep vein thrombosis (DVT) and pulmonary embolism (PE) during the acute recovery period. The short-term trials reported measurements that indicated differences in VTE event incidence when compared to control groups receiving placebo or no treatment. The evidence structure for this surgical setting is characterized by a high degree of consistency across the available trials.

In the context of acute medical illness, studies focused on high-risk, immobilized adult patients. These trials monitored DVT incidence and reported data indicating differences when compared to control groups. However, due to the inclusion of heterogeneous patient types (e.g., heart failure, respiratory issues), the consistency of the evidence for this specific indication is generally characterized as moderate.

---

Evidence for Treating Existing Blood Clots

For the treatment of established DVT and PE, trials often compared nadroparin against the historical standard, Unfractionated Heparin (UFH). Researchers monitored the rate of clot recurrence. The trials reported data that showed patterns related to those observed in the UFH groups during the initial treatment phase, establishing an evidence structure with a high degree of consistency for this use.

---

Research Gaps and Uncertainty

Long-term research on the use of this medicine beyond the initial few weeks remains less established. Long-term VTE outcomes and observations of extended outpatient use are not fully characterized by the core evidence from the initial trials. There is also a lack of dedicated, head-to-head comparative research against the newer Direct Oral Anticoagulants (DOACs) for the acute treatment phase. Research is ongoing to better understand the application and measured study findings of this medicine compared to other evolving treatment strategies.

Key Studies & References

1. Summary of Product Characteristics (SPC) for Nadroparin (HPRA Document CRN00CW67)
2. Attachment: Extract from Clinical Evaluation: Nadroparin (TGA Report PM-2016-02215-1-3)

Common questions about Fraxodi (FAQ)

---

Q: When do I take Fraxodi—once or twice a day?

According to official product information, Fraxodi may be administered either once daily or twice daily (every 12 hours). The prescribed frequency is determined by a healthcare professional. This schedule depends on the specific treatment regimen being followed, such as whether the medicine is used for prevention or for treating an existing clot.

---

Q: Can children or teenagers be treated with Fraxodi?

Regulatory documents state that use in children and adolescents (under 18) is not recommended. This is because official regulatory documents cite insufficient data to establish appropriate dosing or safety in this age group.

---

Q: Are there any pain management medicines that I must not take with Fraxodi?

Official documents advise caution regarding co-administration with several other medicine classes that can increase the risk of bleeding. This includes products like NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Platelet Inhibitors, Oral Anticoagulants, and Thrombolytic Agents. These combinations are documented to have an additive effect that increases the risk of bleeding complications.

---

Q: What is the correct angle to insert the needle for my injection?

The official guidance specifies that the needle should be inserted into the pinched-up fold of skin at either a vertical (90-degree angle) or a 45-degree angle. This technique is documented in the procedural steps for injection.

---

Q: Does Fraxodi thin the blood immediately?

Regulatory documents state that Nadroparin provides an antithrombotic effect. Peak anti-Xa activity, which is a measure of its clot-inhibiting effect, is typically reached in the blood about 3 to 6 hours after subcutaneous injection.

---

Q: For how long can I expect to be taking Fraxodi?

The duration of treatment varies based on the patient's specific medical condition and indication. For example, in the treatment of a Deep Venous Thrombosis (DVT), the duration is defined in regulatory documents as at least 5 days and must continue until the patient achieves adequate oral anticoagulation. Treatment for prophylaxis may continue for a different duration, such as at least 7 days in some cases.

---

Q: Is Fraxodi a type of Heparin?

Yes. Fraxodi’s active ingredient, Nadroparin Calcium, belongs to the class of medicines called Low Molecular Weight Heparin (LMWH). This means it is a modified, semi-synthetic derivative of the original parent compound, Heparin.

Storage Conditions

Fraxodi (nadroparin calcium) must be stored according to specific environmental controls to maintain product stability, as documented in official regulatory labeling.

• Temperature: Store the product at or below 25 C.
• Prohibitions: It is mandatory that Fraxodi must not be frozen and should not be stored in a refrigerator.
• Protection: Keep the pre-filled syringes in the original container and out of the sight and reach of children.

---

Disposal Instructions

Disposal must adhere to local pharmaceutical waste protocols due to the product being a pharmaceutical sharp.

• General Rule: Unused medicinal product and waste material must be discarded in accordance with local requirements.
• Sharps: Used pre-filled syringes must not be thrown away in household waste; specialized sharps disposal methods should be used.